» Articles » PMID: 6243744

(ADP-ribose)n Participates in DNA Excision Repair

Overview
Journal Nature
Specialty Science
Date 1980 Feb 7
PMID 6243744
Citations 261
Authors
Affiliations
Soon will be listed here.
Abstract

Chromatin proteins are covalently modified by at least five different processes; in no case has the precise physiological function been established. One of these post-synthetic, covalent modifications is effected by the enzyme poly(ADP-ribose) polymerase, which uses the coenzyme NAD+ to ADP-ribosylate chromatin proteins. The modification consists largely of mono(ADP-ribose), but long, homopolymer chains of (ADP-ribose) are also present. Various physiological functions have been suggested for (ADP-ribose)n. Here we demonstrate that one function of (ADP-ribose)n is to participate in the cellular recovery from DNA damage. Specific inhibitors of poly(ADP-ribose) polymerase prevent rejoining of DNA strand breaks caused by dimethyl sulphate and cytotoxicity is enhanced thereby. The rejoining of strand breaks is prevented also by nutritionally depleting the cells of NAD.

Citing Articles

The clinically applied PARP inhibitor talazoparib ameliorates imiquimod-induced psoriasis in mice without reducing skin inflammation.

Molnar P, Demeny M, Varkonyi B, Polgar Z, Por A, Kovacs I Front Pharmacol. 2025; 16:1519066.

PMID: 40046735 PMC: 11879949. DOI: 10.3389/fphar.2025.1519066.


Single-molecule analysis of PARP1-G-quadruplex interaction.

Gaur P, Bain F, Meah R, Spies M bioRxiv. 2025; .

PMID: 39829912 PMC: 11741300. DOI: 10.1101/2025.01.06.631587.


DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications.

Drew Y, Zenke F, Curtin N Nat Rev Drug Discov. 2024; 24(1):19-39.

PMID: 39533099 DOI: 10.1038/s41573-024-01060-w.


Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions.

Bondar D, Karpichev Y Biomolecules. 2024; 14(10).

PMID: 39456202 PMC: 11506039. DOI: 10.3390/biom14101269.


Fertility protection during chemotherapy treatment by boosting the NAD(P) metabolome.

Ho W, Marinova M, Listijono D, Bertoldo M, Richani D, Kim L EMBO Mol Med. 2024; 16(10):2583-2618.

PMID: 39169162 PMC: 11473878. DOI: 10.1038/s44321-024-00119-w.